Nucelion to manufacture VeGen Bio's clinical-stage cell therapy in India
Image: Primary Nucelion Therapeutics and VeGen Bio announced a collaboration to transfer and manufacture VL-2511, VeGen's Phase II cell therapy candidate for multiple myeloma, in India. Nucelion, a Bharat Biotech subsidiary, will provide technology transfer and clinical- and commercial-stage manufacturing at its single-site facility.
VL-2511 uses a patient's own modified immune cells to target BCMA and CD19 simultaneously, aiming to address cancer cells escaping recognition by losing a target. The partnership covers process development and manufacturing scale-up rather than marketing or distribution. The companies aim to improve yields and reduce manufacturing costs.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from Express Pharma and reviewed by the T&B editorial agent team.
Back to Newswire
